Related Experiment Video
Updated: Mar 7, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
Nicholas McGranahan1, Charles Swanton2
1Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK; Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK.
Intratumor heterogeneity drives cancer evolution and drug resistance. Novel therapeutic strategies targeting tumor evolution and the microenvironment are crucial for improving patient outcomes.
Area of Science:
- Oncology
- Evolutionary Biology
- Genetics
Background:
- Intratumor heterogeneity is a significant obstacle in cancer medicine, promoting tumor evolution.
- Understanding the dynamics of tumor evolution is critical for developing effective cancer therapies.
Purpose of the Study:
- To review current data and technologies elucidating intra-tumor heterogeneity.
- To discuss the evolutionary dynamics, constraints, and contingencies in cancer.
- To highlight the role of macro-evolutionary leaps and the tumor microenvironment.
Main Methods:
- Review of existing data and technological advancements in cancer research.
- Analysis of evolutionary principles applied to tumor development.
- Examination of the tumor microenvironment's influence on heterogeneity and drug resistance.
Main Results:
- Intra-tumor heterogeneity is prevalent across various cancer types.
- Macro-evolutionary leaps, including chromosomal alterations, are key drivers of tumor evolution and metastasis.
- The tumor microenvironment significantly contributes to heterogeneity and the development of drug resistance.
Conclusions:
- Novel drug development approaches are needed, focusing on adaptive immune-microenvironment properties.
- Limiting tumor adaptive properties and advancing clinical trial design are essential.
- Improved patient outcomes can be achieved through integrated therapeutic and trial strategies.
More Related Videos
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
07:54Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer